Last updated: February 16, 2026
Overview of the Drug
NDC 00002-1445 corresponds to Doxil (doxorubicin HCl liposomal injection), a chemotherapy agent used primarily for ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma. As a liposomal formulation of doxorubicin, it was developed to reduce cardiotoxicity associated with traditional doxorubicin. The drug was originally approved by the FDA in 1995 and has maintained a significant role in oncology treatment.
Market Landscape
The oncology drug market for liposomal doxorubicin formulations, including Doxil and generic equivalents, has been influenced by multiple factors:
-
Market Size: Estimated at approximately USD 700 million in global sales (2022). The US accounts for around 60% of sales.
-
Key Competitors: Besides Doxil, generic versions are available post-patent expiration, resulting in competitive pricing pressure.
-
Patent Status: Doxil was under patent protection until 2020. The expiration has resulted in increased generic competition, driving prices downward.
-
Pricing Dynamics: Before patent expiration, Doxil's wholesale acquisition cost (WAC) hovered around USD 2,000 per vial (20 mg). Post-expiration, generic prices decreased, with some brands offering the same dosage at approximately USD 700-1,200 per vial.
-
Regulatory Actions: In 2021, the FDA approved Liposomal Doxorubicin HCl Injection generics, increasing supply and decreasing prices further.
Current Market Trends
-
The off-label use of liposomal doxorubicin, especially for recurrent ovarian cancer, sustains demand.
-
The adoption of biosimilars is increasing due to cost-effectiveness and comparable efficacy.
-
The impact of COVID-19 delayed elective treatments but caused increased adoption of outpatient chemotherapy, potentially stabilizing demand.
Price Projections (2023-2027)
| Year |
Estimated Price Range per Vial |
Rationale |
| 2023 |
USD 700 - USD 1,200 |
Post-generic entry, prices stabilized after initial decline. |
| 2024 |
USD 650 - USD 1,000 |
Competitive pressure persists; prices remain downward. |
| 2025 |
USD 600 - USD 900 |
Market consolidation and increased biosimilar options. |
| 2026 |
USD 550 - USD 850 |
Continued demand for established indications; price stabilization expected. |
| 2027 |
USD 500 - USD 800 |
Generic saturation; further price reductions possible. |
Factors Influencing Price Changes
- Patent and exclusivity: Patent expiry in 2020 triggered discounting and generic competition.
- Market penetration of biosimilars: Expected to increase from 15% (2023) to over 40% (2027).
- Reimbursement policies: Favor lowest-cost options, pressuring prices downward.
- Manufacturing costs: Remain relatively stable, limiting significant price increases unless new formulations or indications emerge.
- Regulatory landscape: Approvals of new formulations or combinations could influence market share.
Implications for Stakeholders
- Pharmaceutical manufacturers: Entry of biosimilars and generics will pressure pricing and margins.
- Healthcare providers: Shift toward cost-saving generic options will affect procurement.
- Investors: The market for this drug is nearing saturation, with limited upside post-generic entry; revenue growth prospects may plateau.
Summary
The initial high pricing of Doxil was driven by patent exclusivity and limited competition. Once patent expiry occurred in 2020, pricing declined significantly, with continued downward pressure due to increasing generic and biosimilar competition. Price stabilization is expected in the near term, with minor reductions over the next five years as market saturation occurs.
Key Takeaways
- NDC 00002-1445 (Doxil) shifted from premium pricing (~USD 2,000 per vial) to mainstream generic prices (~USD 700-USD 1,200 per vial) following patent expiration.
- Market competition, biosimilar entry, and payer strategies will continue to suppress prices.
- Future prices are projected to decline gradually, stabilizing between USD 500 and USD 800 per vial by 2027.
- Demand remains driven by off-label use and oncology indications, but growth is limited given market saturation.
- Stakeholders should align strategies with evolving regulation and competitive pressures to optimize portfolio positioning.
5 FAQs
1. How has patent expiration impacted the pricing of NDC 00002-1445?
Patent expiry in 2020 led to an influx of generic products, causing wholesale prices to fall from approximately USD 2,000 to below USD 1,200 per vial.
2. What is the current market size for liposomal doxorubicin drugs?
Global sales are estimated at USD 700 million annually, with the US accounting for about 60%.
3. Will biosimilars significantly reduce the price of this drug?
Yes, biosimilars are expected to capture over 40% of the market share by 2027, further driving prices downward.
4. What factors could alter the price projections?
Regulatory changes, new indications, patent disputes, or supply chain disruptions could cause deviations from projections.
5. Is there potential for price increases due to new indications?
While possible, such developments are unlikely in the near term due to market saturation and regulatory hurdles.
References
- IQVIA – Global Oncology Market Data, 2022.
- U.S. Food and Drug Administration (FDA) – Approval history and generic authorizations, 2021.
- MarketWatch – Oncology drug market analysis, 2023.
- Evaluate Pharma – Pricing and sales forecasts, 2022.
- FDA – Biosimilar approvals and market impact reports, 2022.
